Head of U.S. Oncology and Immuno-Oncology Research
Dale Porter is the Head of US Oncology and Immuno-Oncology Research at Servier Pharmaceuticals. In his role, Dale is responsible for leading the research team focused on the discovery and development of new drugs in oncology and immuno-oncology.
With more than 20 years of experience in building and leading drug discovery teams in biotech and pharmaceutical companies, Dale is an experienced leader who has led both large and small teams alike. Prior to Servier, Dale was Head of Biology at Cedilla Therapeutics, a biotech developing novel protein degrader and conditional inhibitor modalities. Dale also worked in leadership positions in both the William Sellers lab at the Broad Institute and Novartis where he built and led scientific and drug discovery teams, and led oncology drug discovery and translational medicine efforts respectfully.
Dale received his Ph.D. in physiology from Cornell University and completed his post-doctoral studies in cancer biology and genomics at the Dana-Farber Cancer Institute and Harvard Medical School.